You just read:

Theravance Biopharma and Mylan to Report New Data from Phase 3 Studies of YUPELRI™ (revefenacin) in Oral Presentation at European Respiratory Society International Congress 2018

News provided by

Theravance Biopharma, Inc. , Mylan N.V.

Sep 11, 2018, 16:22 ET